TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference
CAMBRIDGE, Mass., Feb. 09, 2022 – TCR2 Therapeutics Inc. (Nasdaq: TCRR) will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 1:40 PM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CAMBRIDGE, Mass., Feb. 09, 2022 – TCR2 Therapeutics Inc. (Nasdaq: TCRR) will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16 at 1:40 PM ET. The session will be held virtually, and a live webcast can be accessed on the Company’s Investors page at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the event.
TCR2 is focused on innovative T cell therapies targeting solid tumors.
Details
News Market Reaction – TCRR
The recorded move for TCRR in the trading session of this news was +6.41%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients suffering from solid tumors, today announced that management will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 16 at 1:40PM E.T. using a virtual platform.
A live webcast of the presentation will be available on the Investors page of the Company’s website at www.investors.tcr2.com. An archived replay will be available for at least 30 days following the presentation.
About TCR2 Therapeutics
TCR2 Therapeutics Inc. is a clinical-stage cell therapy company developing a pipeline of novel T cell therapies for cancer patients suffering from solid tumors. The company is focused on the discovery and development of product candidates against novel and complex targets utilizing its proprietary T cell receptor (TCR) Fusion Construct T cells (TRuC®-T cells). The TRuC platform is designed to specifically recognize and kill cancer cells by harnessing signaling from the entire TCR, independent of human leukocyte antigens (HLA). For more information about TCR2, please visit www.tcr2.com.
Investor and Media Contacts:
TCR2 Therapeutics
Carl Mauch
Senior Director, Investor Relations and Corporate Communications
(617) 949-5667
carl.mauch@tcr2.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.